These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
434 related articles for article (PubMed ID: 1316227)
1. Development and characterization of a WEHI-3B D+ monomyelocytic leukemia cell line resistant to novobiocin and cross-resistant to other topoisomerase II-targeted drugs. Rappa G; Lorico A; Sartorelli AC Cancer Res; 1992 May; 52(10):2782-90. PubMed ID: 1316227 [TBL] [Abstract][Full Text] [Related]
2. Increased rate of adenosine triphosphate-dependent etoposide (VP-16) efflux in a murine leukemia cell line overexpressing the multidrug resistance-associated protein (MRP) gene. Lorico A; Rappa G; Srimatkandada S; Catapano CV; Fernandes DJ; Germino JF; Sartorelli AC Cancer Res; 1995 Oct; 55(19):4352-60. PubMed ID: 7671247 [TBL] [Abstract][Full Text] [Related]
3. Induction of the differentiation of WEHI-3B D+ monomyelocytic leukemia cells by inhibitors of topoisomerase II. Rappa G; Lorico A; Sartorelli AC Cancer Res; 1990 Oct; 50(20):6723-30. PubMed ID: 2170008 [TBL] [Abstract][Full Text] [Related]
4. Reversal of etoposide resistance in non-P-glycoprotein expressing multidrug resistant tumor cell lines by novobiocin. Rappa G; Lorico A; Sartorelli AC Cancer Res; 1993 Nov; 53(22):5487-93. PubMed ID: 8106148 [TBL] [Abstract][Full Text] [Related]
5. Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance. Schneider E; Horton JK; Yang CH; Nakagawa M; Cowan KH Cancer Res; 1994 Jan; 54(1):152-8. PubMed ID: 7903202 [TBL] [Abstract][Full Text] [Related]
6. Altered topoisomerase I and II activities in suramin-resistant lung fibrosarcoma cells. Lelièvre S; Benchokroun Y; Larsen AK Mol Pharmacol; 1995 May; 47(5):898-906. PubMed ID: 7746278 [TBL] [Abstract][Full Text] [Related]
7. Topoisomerase II as a target of VM-26 and 4'-(9-acridinylamino)methanesulfon-m-aniside in atypical multidrug resistant human small cell lung carcinoma cells. de Jong S; Kooistra AJ; de Vries EG; Mulder NH; Zijlstra JG Cancer Res; 1993 Mar; 53(5):1064-71. PubMed ID: 8382551 [TBL] [Abstract][Full Text] [Related]
8. Characterization of a subline of P388 leukemia resistant to amsacrine: evidence of altered topoisomerase II function. Per SR; Mattern MR; Mirabelli CK; Drake FH; Johnson RK; Crooke ST Mol Pharmacol; 1987 Jul; 32(1):17-25. PubMed ID: 3037302 [TBL] [Abstract][Full Text] [Related]
9. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines. Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249 [TBL] [Abstract][Full Text] [Related]
10. Combined modalities of resistance in etoposide-resistant human KB cell lines. Ferguson PJ; Fisher MH; Stephenson J; Li DH; Zhou BS; Cheng YC Cancer Res; 1988 Nov; 48(21):5956-64. PubMed ID: 2844393 [TBL] [Abstract][Full Text] [Related]
11. Trifluoperazine modulation of resistance to the topoisomerase II inhibitor etoposide in doxorubicin resistant L1210 murine leukemia cells. Kamath N; Grabowski D; Ford J; Drake F; Kerrigan D; Pommier Y; Ganapathi R Cancer Commun; 1991 Feb; 3(2):37-44. PubMed ID: 1995027 [TBL] [Abstract][Full Text] [Related]
12. Altered DNA-cleavage activity of topoisomerase II from WEHI-3B leukemia cells with specific resistance to ciprofloxacin. Pessina A; Raimondi A; Croera C; Acchini M; Mineo E; Foti P; Neri MG Anticancer Drugs; 2001 Jun; 12(5):441-51. PubMed ID: 11395572 [TBL] [Abstract][Full Text] [Related]
13. Characterization of an unusual mutant of human melanoma cells resistant to anticancer drugs that inhibit topoisomerase II. Campain JA; Padmanabhan R; Hwang J; Gottesman MM; Pastan I J Cell Physiol; 1993 May; 155(2):414-25. PubMed ID: 8097746 [TBL] [Abstract][Full Text] [Related]
14. Development and properties of an etoposide-resistant human leukaemic CCRF-CEM cell line. Patel S; Austin CA; Fisher LM Anticancer Drug Des; 1990 Feb; 5(1):149-57. PubMed ID: 2156515 [TBL] [Abstract][Full Text] [Related]
15. Increased phosphorylation of DNA topoisomerase II in etoposide-resistant mutants of human cancer KB cells. Takano H; Kohno K; Ono M; Uchida Y; Kuwano M Cancer Res; 1991 Aug; 51(15):3951-7. PubMed ID: 1649696 [TBL] [Abstract][Full Text] [Related]
16. Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIalpha and altered G(2)/M checkpoint and apoptotic responses. Morgan SE; Cadena RS; Raimondi SC; Beck WT Mol Pharmacol; 2000 Feb; 57(2):296-307. PubMed ID: 10648639 [TBL] [Abstract][Full Text] [Related]
17. Genetic characterization of the multidrug-resistant phenotype of VM-26-resistant human leukemic cells. Wolverton JS; Danks MK; Schmidt CA; Beck WT Cancer Res; 1989 May; 49(9):2422-6. PubMed ID: 2539902 [TBL] [Abstract][Full Text] [Related]
18. Mechanisms of resistance to etoposide and teniposide in acquired resistant human colon and lung carcinoma cell lines. Long BH; Wang L; Lorico A; Wang RC; Brattain MG; Casazza AM Cancer Res; 1991 Oct; 51(19):5275-83. PubMed ID: 1717144 [TBL] [Abstract][Full Text] [Related]
19. Decreased DNA topoisomerase II alpha expression and cold-sensitive growth in a mouse mammary cancer cell line resistant to etoposide and doxorubicin. Kawanami K; Nakamura T; Ono M; Kusano T; Okada K; Kikuchi A; Adachi N; Kohno K; Higashi K; Kuwano M Oncol Res; 1996; 8(5):197-206. PubMed ID: 8884812 [TBL] [Abstract][Full Text] [Related]
20. Reduced phosphorylation of topoisomerase II in etoposide-resistant human leukemia K562 cells. Ritke MK; Allan WP; Fattman C; Gunduz NN; Yalowich JC Mol Pharmacol; 1994 Jul; 46(1):58-66. PubMed ID: 8058057 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]